These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 474180)

  • 21. Effect of saralasin on plasma aldosterone in hypertensive man.
    Brown RD; Tucker R; Tue K; Wisgerhof M; Salassa R
    J Lab Clin Med; 1978 Mar; 91(3):473-9. PubMed ID: 627750
    [No Abstract]   [Full Text] [Related]  

  • 22. [Saralasin in subjects with low renin arterial hypertension].
    Frisina N; Buemi M; Lasco A; Macrí I; Ciraolo O; Nicita Mauro V; Costa G
    Boll Soc Ital Biol Sper; 1980 Jul; 56(13):1367-73. PubMed ID: 7004464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of furosemide stimulation on renin secretion and its application in examining activity of the renin-angiotensin system.
    Zofková I
    Cor Vasa; 1976; 18(4):304-9. PubMed ID: 1022409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between blood pressure and renin, angiotensin II and atrial natriuretic factor after renal transplantation.
    Hestin D; Mertes PM; Hubert J; Claudon M; Mejat E; Renoult E; Pertek JP; Frimat L; Burlet C; Kessler M
    Clin Nephrol; 1997 Aug; 48(2):98-103. PubMed ID: 9285146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Regulation of the renin-angiotensin system].
    Kimlová I; Sternová H; Stredová M; Vísek V; Musil J
    Cas Lek Cesk; 1973 Apr; 112(15):470-4. PubMed ID: 4349120
    [No Abstract]   [Full Text] [Related]  

  • 26. The use of saralasin in the recognition of angiotensinogenic hypertension.
    Streeten DH; Dalakos TG; Anderson GH
    Prog Biochem Pharmacol; 1976; 12():214-26. PubMed ID: 1019165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Functional state of the renin-angiotensin system in the diuretic therapy of hypertension].
    Nekrasova AA; Mergenbaeva TK
    Kardiologiia; 1981 Mar; 21(3):19-23. PubMed ID: 7014975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.
    Schwartz GL; Bailey K; Chapman AB; Boerwinkle E; Turner ST
    Am J Hypertens; 2013 Aug; 26(8):957-64. PubMed ID: 23591988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical usefulness of saralasin in human hypertension (author's transl)].
    Fouchard M; Bichara M; Grüfeld JP; Barbanel C; Meyer P; Funck-Brentano JL
    Nouv Presse Med; 1978 Feb; 7(7):539-43. PubMed ID: 643579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The renin-angiotensin-aldosterone system in essential arterial hypertension].
    Ruilope L; Alcazar JM; García Robles R; Gutiérrez Millet V; Jarillo MD; Torres J; Morales JM; Rodicio JL
    Rev Clin Esp; 1977 Sep; 146(5):233-7. PubMed ID: 928859
    [No Abstract]   [Full Text] [Related]  

  • 32. The role of the renin--angiotensin--aldosterone system in cardiovascular homeostasis in normal man.
    Haber E; Sancho J; Re R; Burton J; Barger AC
    Clin Sci Mol Med Suppl; 1975 Jun; 2():49s-52s. PubMed ID: 1077790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.
    Azizi M; Guyene TT; Chatellier G; Ménard J
    J Hypertens; 1994 Apr; 12(4):419-27. PubMed ID: 8064166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of acute and chronic administration of propranolol on blood pressure and plasma renin activity in hypertensive patients.
    Stokes GS; Weber MA; Thornell IR; Stoker LM
    Prog Biochem Pharmacol; 1974; 9():29-44. PubMed ID: 4612559
    [No Abstract]   [Full Text] [Related]  

  • 35. [Renin-angiotensin-aldosterone system in essential hypertension].
    Kono T; Yoshimi T; Endo J; Kawaguchi Y; Sakai T
    Nihon Rinsho; 1973 Nov; 31(11):3177-81. PubMed ID: 4360309
    [No Abstract]   [Full Text] [Related]  

  • 36. Moderate sodium restriction, angiotensin converting enzyme inhibition, and thiazide diuretic in the management of essential hypertension.
    Singer DR; Markandu ND; Furnival L; Khoshnodi L; MacGregor GA
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S5-7. PubMed ID: 2474103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Interrelationship between plasma renin activity and angiotensin II level --A preliminary analysis of 773 samples from normotensives and essential hypertensives (author's transl)].
    Li DY
    Zhonghua Xin Xue Guan Bing Za Zhi; 1981 Sep; 9(3):192-6. PubMed ID: 7040013
    [No Abstract]   [Full Text] [Related]  

  • 38. [Preliminary study on plasma 6-keto-prostaglandin F1 alpha levels before and after induction by furosemide in hypertensive patients].
    Zhao GS; Yuan XY; Shen XY
    Zhonghua Xin Xue Guan Bing Za Zhi; 1987 Jun; 15(3):134-6, 190. PubMed ID: 3325249
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical implications of renin in the hypertensive patient.
    Brunner HR; Gavras H
    JAMA; 1975 Sep; 233(10):1091-3. PubMed ID: 1174160
    [No Abstract]   [Full Text] [Related]  

  • 40. [Na metabolism anomaly in essential hypertension].
    Mizukoshi H; Araki Y
    Nihon Rinsho; 1973 Nov; 31(11):3157-62. PubMed ID: 4360306
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.